Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer

Molecular Cancer Therapeutics

Volumn 13, Issue 4, 2014, Pages 902-915

  Fu, Maoyong ^a   Maresh, Erin L ^a   Helguera, Gustavo F ^a,d   Kiyohara, Meagan ^a   Qin, Yu ^a   Ashki, Negin ^a   Daniels Wells, Tracy R ^a   Aziz, Najib ^a   Gordon, Lynn K ^a,b   Braun, Jonathan ^a   Elshimali, Yahya ^b   Soslow, Robert A ^c   Penichet, Manuel L ^a   Goodglick, Lee ^a   Wadehra, Madhuri ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPITHELIAL MEMBRANE PROTEIN 2; EPITHELIAL MEMBRANE PROTEIN 2 IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; MEMBRANE PROTEIN; PROTEIN ANTIBODY; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; EMP2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY STRUCTURE; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOMA; BREAST HYPERPLASIA; CANCER IMMUNOTHERAPY; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG HALF LIFE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; LYMPH NODE METASTASIS; MONOTHERAPY; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH; TUMOR INVASION; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DRUG EFFECTS; DRUG SCREENING; EXPERIMENTAL MAMMARY NEOPLASM; GENE EXPRESSION REGULATION; LUNG NEOPLASMS; METABOLISM; MOLECULARLY TARGETED THERAPY; SECONDARY; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS; TRIPLE NEGATIVE BREAST NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901070783     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0199     Document Type: Article

References (49)

1. Higgins MJ, Baselga J. Targeted therapies for breast cancer. J Clin Invest 2011;121:3797-803.
2. Elias AD. Triple-negative breast cancer: a short review. AmJ Clin Oncol 2010;33:637-45.
3. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010;363:1938-48.
4. Weigelt B, Peterse JL, van 't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer 2005;5:591-602.
5. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
6. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008:GLOBOCAN2008. Int J Cancer 2010;127:2893-917.
7. Fu M, Maresh EL, Soslow RA, Alavi M, Mah V, Zhou Q, et al. Epithelial membrane protein-2 is a novel therapeutic target in ovarian cancer. Clin Cancer Res 2010;16:3954-63.
8. Habeeb O, Goodglick L, Soslow RA, Rao RG, Gordon LK, Schirripa O, et al. Epithelial membrane protein-2 expression is an early predictor of endometrial cancer development. Cancer 2010;116:4718-26.
9. Wadehra M, Natarajan S, Seligson DB, Williams CJ, Hummer AJ, Hedvat C, et al. Expression of epithelial membrane protein-2 is associated with endometrial adenocarcinoma of unfavorable outcome. Cancer 2006;107:90-8.
10. Gordon LK, Kiyohara M, Fu M, Braun J, Chan AM, Goodglick L, et al. EMP2 regulates angiogenesis in endometrial cancer cells through induction of VEGF. Oncogene 2013;32:5369-76.
11. Fu M, Rao R, Sudhakar D, Hogue CP, Rutta Z, Morales S, et al. Epithelial membrane protein-2 promotes endometrial tumor formation through activation of FAK and Src. PLoS ONE 2011;6:e19945.
12. Morales SA, Mareninov S, Coulam P, Wadehra M, Goodglick L, Braun J, et al. Functional consequences of interactions between FAK and epithelial membrane protein 2 (EMP2). Invest Ophthalmol Vis Sci 2009;50:4949-56.
13. Morales SA, Mareninov S, Prasad P, Wadehra M, Braun J, Gordon LK. Collagen gel contraction by ARPE-19 cells is mediated by a FAK-Src dependent pathway. Exp Eye Res 2007;85:790-8.
14. Morales SA, Mareninov S, Wadehra M, Zhang L, Goodglick L, Braun J, et al. FAKactivation and the role of epithelial membrane protein 2 (EMP2) in collagen gel contraction. Invest Ophthalmol Vis Sci 2009;50:462-9.
15. Wadehra M, Forbes A, Pushkarna N, Goodglick L, Gordon LK, Williams CJ, et al. Epithelial membrane protein-2 regulates surface expression of alphavbeta3 integrin in the endometrium. Dev Biol 2005;287:336-45.
16. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
17. Obermayr E, Sanchez-Cabo F, Tea MK, Singer CF, Krainer M, Fischer MB, et al. Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients. BMC Cancer 2010;10:666.
18. Kao J, Salari K, Bocanegra M, Choi YL, Girard L, Gandhi J, et al. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS ONE 2009;4:e6146.
19. Watson MA, Ylagan LR, Trinkaus KM, Gillanders WE, Naughton MJ, Weilbaecher KN, et al. Isolation and molecular profiling of bone marrow micrometastases identifies TWIST1 as a marker of early tumor relapse in breast cancer patients. Clin Cancer Res 2007;13:5001-9.
20. Shimazaki K, Lepin EJ, Wei B, Nagy AK, Coulam CP, Mareninov S, et al. Diabodies targeting epithelial membrane protein 2 reduce tumorigenicity of human endometrial cancer cell lines. Clin Cancer Res 2008;14:7367-77.
21. Yoon NK, Seligson DB, Chia D, Elshimali Y, Sulur G, Li A, et al. Higher expression levels of 14-3-3sigma in ductal carcinoma in situ of the breast predict poorer outcome. Cancer Biomark 2009;5:215-24.
22. Presson AP, Yoon NK, Bagryanova L, Mah V, Alavi M, Maresh EL, et al. Protein expression based multimarker analysis of breast cancer samples. BMC Cancer 2011;11:230.
23. Xuan C, Steward KK, Timmerman JM, Morrison SL. Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma. Blood 2010;115:2864-71.
24. Helguera G, Penichet ML. Antibody-cytokine fusion proteins for the therapy of cancer. Methods Mol Med 2005;109:347-74.
25. Qu Z, Griffiths GL, Wegener WA, Chang C-H, Govindan SV, Horak ID, et al. Development of humanized antibodies as cancer therapeutics. Methods 2005;36:84-95.
26. Morrison SL, Wims L, Wallick S, Tan L, Oi VT. Genetically engineered antibody molecules and their application. Ann N Y Acad Sci 1987;507:187-98.
27. Wadehra M, Sulur GG, Braun J, Gordon LK, Goodglick L. Epithelial Membrane Protein-2 is expressed in discrete anatomical regions of the eye. Exp Mol Pathol 2003;74:106-12.
28. Colello D, Mathew S, Ward R, Pumiglia K, LaFlamme SE. Integrins regulate microtubule nucleating activity of centrosome through mitogen- activated protein kinase/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase (MEK/ERK) signaling. J Biol Chem 2012;287:2520-30.
29. Zhang SQ, Yang W, Kontaridis MI, Bivona TG, Wen G, Araki T, et al. Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment. Mol Cell 2004;13:341-55.
30. Yoon NK, Maresh EL, Elshimali Y, Li A, Horvath S, Seligson DB, et al. Elevated MED28 expression predicts poor outcome in women with breast cancer. BMC Cancer 2010;10:335.
31. Yoon NK, Maresh EL, Shen D, Elshimali Y, Apple S, Horvath S, et al. Higher levels of GATA3 predict better survival in women with breast cancer. Hum Pathol 2010;41:1794-801.
32. Shen D, Nooraie F, Elshimali Y, Lonsberry V, He J, Bose S, et al. Decreased expression of annexin A1 is correlated with breast cancer development and progression as determined by a tissue microarray analysis. Hum Pathol 2006;37:1583-91.
33. Mah V, Seligson DB, Li A, Marquez DC, Wistuba II, Elshimali Y, et al. Aromatase expression predicts survival in women with early-stage non small cell lung cancer. Cancer Res 2007;67:10484-90.
34. Zhao H, Langerød A, Ji Y, Nowels KW, Nesland JM, Tibshirani R, et al. Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell 2004;15:2523-36.
35. Ma X-J, Dahiya S, Richardson E, Erlander M, Sgroi D. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res 2009;11:R7.
36. Pal SK, Childs BH, Pegram M. Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat 2011;125:627-36.
37. Holliger P, Prospero T, Winter G. "Diabodies": small bivalent and bispecific antibody fragments. Proc Natl Acad Sci U S A 1993;90:6444-8.
38. Fu M, Brewer S, Olafsen T, Wu A, Gordon L, Said J, et al. Positron emission tomography imaging of endometrial cancer using engineered anti-EMP2 antibody fragments. Mol Imaging Biol 2013;15:68-78.
39. Ma L, Reinhardt F, Pan E, Soutschek J, Bhat B, Marcusson EG, et al. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotech 2010;28:341-7.
40. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004;117:927-39.
41. Hortobagyi GN. Toward individualized breast cancer therapy: translating biological concepts to the bedside. Oncologist 2012;17:577-84.
42. Wadehra M, Iyer R, Goodglick L, Braun J. The tetraspan protein epithelial membrane protein-2 interacts with beta1 integrins and regulates adhesion. J Biol Chem 2002;277:41094-100.
43. Burgess DJ. Breast cancer: SRC hits the mark. Nat Rev Cancer 2011;11:314-5.
44. Zhang S, Huang W-C, Li P, Guo H, Poh S-B, Brady SW, et al. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med 2011;17:461-9.
45. Zhang XHF, Wang Q, Gerald W, Hudis CA, Norton L, Smid M, et al. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 2009;16:67-78.
46. Rucci N, Recchia I, Angelucci A, Alamanou M, Del Fattore A, Fortunati D, et al. Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy. J Pharmacol Exp Ther 2006;318:161-72.
47. Dahlin K, Mager EM, Allen L, Tigue Z, Goodglick L, Wadehra M, et al. Identification of genes differentially expressed in rat alveolar type I cells. Am J Respir Cell Mol Biol 2004;31:309-16.
48. Nahta R, Yu D, Hung M-C, Hortobagyi GN, Esteva FJ. Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Prac Oncol 2006;3:269-80.
49. Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012;12:237-51.